<DOC>
	<DOCNO>NCT00531167</DOCNO>
	<brief_summary>Antiviral resistance mutation limit efficacy therapy chronic hepatitis B . At year 2 , resistance adefovir may occur high 25 % patient history lamivudine resistance . Resistance entecavir report 10 % lamivudine refractory patient period . However , combination lamivudine adefovir decrease adefovir resistance rate low 0 % recent study . By overcome antiviral resistance , efficacy therapy maximize . This study intend compare efficacy two strategy , combination lamivudine adefovir vs. entecavir monotherapy patient lamivudine resistance .</brief_summary>
	<brief_title>Adding Adefovir Dipivoxil Versus Switching Entecavir Patients With Lamivudine-resistant Chronic Hepatitis B</brief_title>
	<detailed_description>Recently , publish data show combination lamivudine adefovir lead PCR negativity ( &lt; 1000 copies/mL ) 80 % treatment lamivudine-resistant chronic hepatitis B year 2 [ Rapti et al . Hepatology 2007 Feb ; 45 ( 2 ) :307-13. ] . Other study also show 76 % 69 % PCR negativity mostly HBeAg negative subject [ Lampertico et al . Hepatology 2006 Oct ; 44 ( 4 ) Suppl 1:556A-557A , Lampertico et al . Hepatology 2006 Oct ; 44 ( 4 ) Suppl 1:693A-694A ] . In study treatment lamivudine-resistant chronic hepatitis B patient include HBeAg positive subject predominantly , entecavir monotherapy show 34 % PCR negativity ( &lt; 300 copies/mL ) year 2 [ Tenney DJ , et al . Antimicrob Agents Chemother . 2007 Mar ; 51 ( 3 ) :902-11 ] . Although assumed combination lamivudine adefovir would effective entecavir monotherapy lamivudine resistant patient , verify assumption , data directly compare two strategy . The aim study determine effective therapy patient lamivudine resistant chronic hepatitis B . We compare PCR negativity ( &lt; 60 IU/ml ) HBV DNA year 2 patient receive 'the combination lamivudine adefovir ' 'entecavir monotherapy ' . Since plan include lamivudine-resistant chronic hepatitis B patient regardless HBeAg status , assume PCR negativity ( &lt; 300 copies/mL &lt; 60 IU/mL ) adefovir-lamivudine combination entecavir monotherapy group 55 % 34 % , respectively , consider HBeAg status low detection limit PCR . The result study able clearly demonstrate superiority combination therapy lamivudine adefovir entecavir monotherapy , provide u guide rescue therapy patient lamivudine resistant HBV .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Adefovir</mesh_term>
	<mesh_term>Adefovir dipivoxil</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>1 . Chronic hepatitis B patient ( positive HBsAg &gt; 6 month ) 2 . Age &gt; 16 year old 3 . Serum alanine aminotransferase ( ALT ) &gt; 1.5 x ULN 4 . History treatment lamivudine 6 month 5 . Proven lamivudine resistant mutation 6 . HBV DNA level &gt; 20000 IU/mL 7 . Compensated liver disease ( ChildPughTurcotte score 7 ; prothrombin time prolong 3 sec ULN INR 1.5 ; serum albumin &gt; 3 g/dL ; total bilirubin &lt; 2.5 mg/dL ; No history variceal bleeding , ascites , hepatic encephalopathy ) 8 . Patients willing give inform consent 1 . Out inclusion criterion 2 . Any one follow Serum phosphorus level 2.4 mg/dL Serum creatinine level 1.5 mg/dL creatinine clearance &lt; 50 mL/min Absolute neutrophil count lower 1000 cell/mL Hb level 10 g/dL ( male ) , 9 g/dL ( female ) Serum AFP &gt; 100 ng/mL 3 . History treatment interferona , thymosinalfa 1 , nucleos ( ) ide analogue lamivudine 6 month screen 4 . Recipient organ transplantation 5 . Positive antibody test HIV , HCV HDV 6 . Pregnant breast feed woman 7 . Patients hepatocellular carcinoma uncontrolled malignant disease 8 . Habitual alcohol drinker ( &gt; 140 g/week men , &gt; 70 g/week woman )</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>lamivudine resistant mutation</keyword>
	<keyword>rescue therapy</keyword>
</DOC>